SCHEMBL30983906

SCHEMBL30983906

CC1(Oc2ncnc3c2nc(-c2ccc(C(=O)O)cc2Cl)n3Cc2ccccc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 3/20 0.39
▸ NR1I2 O75469 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ CNR1 P21554 4/20 0.35
▸ CNR2 P34972 4/20 0.35
▸ EGLN2 Q96KS0 1/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.35
▸ EGLN3 Q9H6Z9 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ RARG P13631 1/20 0.34
▸ DAPK1 P53355 1/20 0.34
▸ MAPK8 P45983 1/20 0.34
▸ AGTR1 P30556 1/20 0.34
▸ AGTR2 P50052 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268855 0.94 CNR1 (0.38) PIK3CDNR1I2HSD11B1CNR1
SCHEMBL31321972 0.93 PIK3CD (0.38) PIK3CDPDE10ACNR1CNR2
SCHEMBL30984005 0.93 CFTR (0.40) PIK3CDPDE10ACNR1CNR2KMT2A
SCHEMBL30983480 0.92 F2 (0.39) PIK3CDPDE10ACNR1CNR2
SCHEMBL31321968 0.92 MAPK14 (0.40) PIK3CDPDE10ACNR1CNR2
SCHEMBL30983776 0.89 PIK3CD (0.40) PIK3CDPDE10ACNR1CNR2KMT2A
SCHEMBL31269475 0.88 PIK3CD (0.37) PIK3CDNR1I2HSD11B1EGLN2EGLN1
SCHEMBL30983826 0.88 PIK3CD (0.39) PIK3CDPDE10ACNR1CNR2KMT2A
SCHEMBL31269290 0.87 PIK3CD (0.37) PIK3CDPDE10ACNR1CNR2
SCHEMBL30983784 0.87 PIK3CD (0.40) PIK3CDPDE10ACNR1CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback